Skip to main content
. 2018 Jul 13;57(11):1938–1946. doi: 10.1093/rheumatology/key203

Table 2.

Achievement of MDA and individual MDA criteria at each visit

Variable Month 0 Month 3 Month 6 Month 9 Month 12 Month 18 Month 24
MDA 0.9 (14/1578) 27.0 (402/1488) 35.5 (597/1684) 37.3 (456/1223) 41.3 (454/1098) 43.3 (398/920) 45.5 (348/764)
TJC ≤1 4.2 (71/1684) 39.6 (647/1635) 46.6 (785/1684) 50.5 (696/1377) 52.5 (658/1253) 54.4 (594/1091) 57.8 (525/909)
SJC ≤1 19.1 (321/1684) 64.0 (588/1635) 70.1 (1180/1684) 71.9 (990/1377) 75.2 (942/1253) 75.5 (824/1091) 81.1 (737/909)
BSA ≤3%a 34.4 (546/1587) 57.0 (863/1513) 64.8 (1901/1684) 66.7 (838/1257) 69.5 (781/1123) 70.7 (666/924) 70.8 (558/788)
Pain ≤1 2.3 (39/1684) 17.1 (276/1614) 21.1 (353/1671) 22.6 (307/1361) 23.9 (293/1228) 24.0 (258/1073) 24.5 (218/890)
PGA ≤2 0.6 (10/1674) 31.5 (513/1629) 40.1 (676/1684) 42.3 (581/1374) 45.1 (564/1251) 47.2 (515/1092) 49.3 (450/912)
Functional remissionb 29.5 (493/1674) 46.4 (750/1618) 47.4 (798/1684) 49.4 (670/1356) 54.0 (662/1226) 52.4 (562/1072) 55.1 (489/888)
No enthesitis 72.7 (1225/1684) 87.1 (1425/1636) 88.8 (1496/1684) 90.3 (1254/1389) 90.3 (1135/1257) 90.6 (997/1100) 92.0 (839/912)

Data are presented as percentage of patients (number of patients who achieved criterion/number of patients with data for the specified outcome at this visit).

a

Baseline (month 0) MDA assessments were based on BSA <3% due to the use of pre-specified categories (<3, 3–10, 11–20 and >20%) for baseline BSA evaluations. Subsequent MDA assessments were based on BSA ≤3% as per the published MDA criterion due to BSA assessments at post-baseline visits as an estimated percentage without pre-specified categorizations.

b

FFbH ≥83% assessed on a scale of 0 (total loss of functional capacity) to 100 (maximal functional capacity). BSA: body surface area; FFbH: Funktionsfragebogen Hannover; MDA: minimal disease activity; PGA: patient global disease activity assessment; SJC: swollen joint count; TJC: tender joint count.